Authors:
McAlister, FA
Lawson, FME
Teo, KK
Armstrong, PW
Citation: Fa. Mcalister et al., Randomised trials of secondary prevention programmes in coronary heart disease: systematic review, BR MED J, 323(7319), 2001, pp. 957-962
Authors:
Bungard, TJ
Ghali, WA
McAlister, FA
Buchan, AM
Cave, AJ
Hamilton, PG
Mitchell, LB
Shuaib, A
Teo, KK
Tsuyuki, RT
Citation: Tj. Bungard et al., Physicians' perceptions of the benefits and risks of warfarin for patientswith nonvalvular atrial fibrillation, CAN MED A J, 165(3), 2001, pp. 301-302
Authors:
Lonn, EM
Yusuf, S
Dzavik, V
Doris, CI
Yi, QL
Smith, S
Moore-Cox, A
Bosch, J
Riley, WA
Teo, KK
Citation: Em. Lonn et al., Effects of ramipril and vitamin E on atherosclerosis - The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitaminE (SECURE), CIRCULATION, 103(7), 2001, pp. 919-925
Authors:
McAlister, FA
Lawson, FME
Teo, KK
Armstrong, PW
Citation: Fa. Mcalister et al., A systematic review of randomized trials of disease management programs inheart failure, AM J MED, 110(5), 2001, pp. 378-384
Authors:
Dzavik, V
Carere, RG
Mancini, GBJ
Cohen, EA
Catellier, D
Anderson, TE
Barbeau, G
Lazzam, C
Title, LM
Berger, PB
Labinaz, M
Teo, KK
Buller, CE
Citation: V. Dzavik et al., Predictors of improvement in left ventricular function after percutaneous revascularization of occluded coronary arteries: A report from the Total Occlusion Study of Canada (TOSCA), AM HEART J, 142(2), 2001, pp. 301-308
Authors:
Anand, SS
Yusuf, S
Vuksan, V
Devanesen, S
Teo, KK
Montague, PA
Kelemen, L
Yi, CL
Lonn, E
Gerstein, H
Hegele, RA
McQueen, M
Citation: Ss. Anand et al., Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE), LANCET, 356(9226), 2000, pp. 279-284
Authors:
Teo, KK
Burton, JR
Buller, CE
Plante, S
Catellier, D
Tymchak, V
Dzavik, V
Taylor, D
Yokoyama, S
Montague, TJ
Citation: Kk. Teo et al., Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis - The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT), CIRCULATION, 102(15), 2000, pp. 1748-1754
Authors:
Cirillo, W
Decanini, R
Coelho, OR
Avezum, A
Peixoto, MSP
Piegas, LS
Neto, JMR
Paiva, M
Carvalho, AC
de Almeida, DR
Fernandes, IML
Malavasi, MC
Pavanello, R
Canesin, M
Ishii, S
Barretto, ACP
Imrie, J
Moore, R
Woo, K
Bernstein, V
Mizgala, HF
Mooney, S
Hilbich, D
Kuritzky, R
Rupka, DW
Blackwell, MM
Breakwell, L
Kornder, JM
Pearce, SA
Polasek, P
Richardson, PM
Grant, J
Isaac, D
Beresford, P
Giannoccaro, P
Roth, D
Greenwood, P
Muzyka, T
Prosser, A
Brass, N
Hui, W
Kvill, L
Goeres, M
MacDonald, K
Senaratne, M
Hill, L
Humen, D
Teo, KK
Habib, N
Habib, N
Teekasingh, S
MacKenzie, J
McEwen, B
Morris, A
Dhair, A
Lai, C
Kwiatkowski, K
Brugos, J
Nawaz, S
Andrews, J
Moe, G
Freskiw, K
Gilbert, B
Morgan, CD
Bozek, B
Halperin, F
Ricci, AJ
Singh, N
Cappelli, G
Boyne, T
Fallen, E
Panju, A
Woodcock, G
Kent, E
Kitching, AD
Sullivan, H
Tomson, D
McKelvie, RS
Tsuyuki, RT
Yusuf, S
Chan, YK
Thomson, D
Arnold, JMO
Hurwitz, G
Miles, R
Baker, A
Haspect, A
Smith, S
Bedard, J
Lavoie, L
Dufort, L
Harvey, R
Lepage, S
Elstein, E
Fitchett, D
Serpa, A
Day, L
Racine, N
Savard, D
Sestier, F
Gosselin, G
Rouleau, JL
White, M
Whittom, L
Kiwan, G
Kouz, SM
Laforest, M
Ouimet, H
Carmichael, P
Lenis, J
Auger, P
Grondin, F
Saulnier, D
Campeau, J
Dupuis, R
Lauzon, C
Genest, M
Robitaille, NM
Beaudoin, J
Belanger, N
Houde, G
Talbot, P
Cossett, J
Koilpillai, C
Sheridan, WJ
Tobin, M
Sussex, B
Ascoli, G
Fraticelli, A
Paciaroni, E
Como, CO
Belluschi, R
Ruffa, F
Tettamanti, F
Cobelli, F
Salvucci, F
Arpesella, R
Campana, C
Gavazzi, A
Cirrincione, V
Ingrilli, F
Sciortino, E
Boccanelli, A
Cacciatore, G
Menichelli, M
Bosimini, E
Giannuzzi, P
Marcassa, C
Porcu, M
Salis, S
Sanna, A
Comerio, G
Gronda, E
Mangiavacchi, M
Moccetti, T
Pasotti, E
Sessa, F
Levy, WC
Probstfield, J
Thompson, J
Gramberg, M
Grover, J
Towery, D
Ogunyankin, K
Singh, BN
Celano, J
Graham, S
Kohn, RM
Pande, P
Sass, A
Wiener, RS
Rydzinski, S
Starling, RC
Young, J
Hays, L
Naftilan, A
Miller, A
Varga, A
Wofford, R
Barnhill, S
Brito, RD
Harris, L
Haspect, A
Cristina, T
Jarosz, M
Kellen, J
Kingry, C
Letterer, R
La Forge, D
Liuni, C
MacKenzie, J
Magi, A
Stevens, K
Squires, P
Yusuf, S
Rouleau, JL
Maggioni, A
Arnold, JMO
Avezum, A
Burns, R
Floras, J
Gavazzi, A
Held, P
Hjalmarson, A
Isaac, D
Latini, R
Lindgren, E
McKelvie, RS
Piegas, LS
Pericak, D
Pogue, J
Probstfield, J
Smith, S
Swedberg, K
Teo, KK
Tsuyuki, RT
Vint-Reed, C
Wang, Y
White, M
Wiecek, EM
Young, J
Johnstone, D
Armstrong, PW
Packer, M
Wedel, H
Teo, KK
Gavazzi, A
Tsuyuki, RT
White, M
McKelvie, R
Anderson, M
Holadyk-Gris, I
Kucemba, K
MacKay, J
McKelvie, RS
Micks, M
Pericak, D
Pogue, J
Reeve, S
Robinson, L
Tsuyuki, RT
Tucker, J
Wiecek, EM
Wang, Y
Yusuf, S
Cernacek, P
Joyal, M
Poitras, N
Rouleau, JL
White, M
Sirois, P
Bevilacqua, M
Latini, R
Masson, S
Torri, M
Hall, C
Burns, RJ
Heeney, T
Tadros, S
White, M
Yusuf, S
McKelvie, RS
Pericak, D
Young, J
Latini, R
Pogue, J
Burns, RJ
Probstfield, J
Tsuyuki, RT
Maggioni, AP
Avezum, A
Rouleau, JL
Citation: W. Cirillo et al., Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy - The randomized evaluation of strategies for left ventricular dysfunction pilot study, CIRCULATION, 101(4), 2000, pp. 378-384
Authors:
Tsuyuki, RT
McAlister, FA
Bungard, TJ
Ghali, WA
Teo, KK
Citation: Rt. Tsuyuki et al., Warfarin therapy for atrial fibrillation: The patient's preference is important - In Reply, ARCH IN MED, 160(15), 2000, pp. 2403-2403
Authors:
Armstrong, PW
Burton, JR
Palisaitis, D
Thompson, CR
Van de Werf, F
Rose, B
Collen, D
Teo, KK
Citation: Pw. Armstrong et al., Collaborative Angiographic Patency Trial of Recombinant Staphylokinase (CAPTORS), AM HEART J, 139(5), 2000, pp. 820-823
Authors:
Tsuyuki, RT
Johnson, JA
Teo, KK
Ackman, ML
Biggs, RS
Cave, A
Chang, WC
Dzavik, V
Farris, KB
Galvin, D
Semchuk, W
Simpson, SH
Taylor, JG
Citation: Rt. Tsuyuki et al., Study of cardiovascular risk intervention by pharmacists (SCRIP): A randomized trial design of the effect of a community pharmacist intervention program on serum cholesterol risk, ANN PHARMAC, 33(9), 1999, pp. 910-919